337 related articles for article (PubMed ID: 26486734)
1. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
[TBL] [Abstract][Full Text] [Related]
2. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
4. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
5. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
[TBL] [Abstract][Full Text] [Related]
8. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
9. Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
Lopez G; Costanza J; Colleoni M; Fontana L; Ferrero S; Miozzo M; Fusco N
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691046
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
11. Genetic and clinical landscape of ER + /PR- breast cancer in China.
Dai D; Wu H; Zhuang H; Chen R; Long C; Chen B
BMC Cancer; 2023 Dec; 23(1):1189. PubMed ID: 38049758
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India.
Singh R; Gupta S; Pawar SB; Pawar RS; Gandham SV; Prabhudesai S
J Cancer Res Ther; 2014; 10(1):26-8. PubMed ID: 24762482
[TBL] [Abstract][Full Text] [Related]
15. Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer.
Tuna M; Smid M; Zhu D; Martens JW; Amos CI
PLoS One; 2010 Nov; 5(11):e15094. PubMed ID: 21152100
[TBL] [Abstract][Full Text] [Related]
16. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
18. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Santarpia L; Qi Y; Stemke-Hale K; Wang B; Young EJ; Booser DJ; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Vidaurre T; Gomez H; Valero V; Hortobagyi GN; Symmans WF; Bottai G; Di Leo A; Gonzalez-Angulo AM; Pusztai L
Breast Cancer Res Treat; 2012 Jul; 134(1):333-43. PubMed ID: 22538770
[TBL] [Abstract][Full Text] [Related]
19. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
